汇丰研究发表报告指，科伦博泰生物(06990.HK) 核心产品SKB264推出仅一个月，销售额已达约5,000万元人民币。强劲临床证据及适应症扩展支持SKB264销售上升。维持“买入”评级；目标价由260元上调至354元。
汇丰研究将科伦博泰生物2025至2026年营收预测调高22%至23%，并净亏损预测调低15%至56%。(ha/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-07 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.